Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. JW (Cayman) Therapeutics Co. Ltd
  6. News
  7. Summary
    2126   KYG5210T1040

JW (CAYMAN) THERAPEUTICS CO. LTD

(2126)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

JW Therapeutics Co. Ltd. Announces Change of Company Secretary

07/30/2021 | 04:31am EST

JW (Cayman) Therapeutics Co. Ltd. announced that Ms. Leung Suet Wing has resigned from her positions as the company secretary, an authorized representative of the Company due to work re-arrangement, with effect from July 30, 2021. The Board announced that Mr. Lee Kwok Fai Kenneth has been appointed as the company secretary, the Authorized Representative and the Process Agent in place of Ms. Leung, with effect from July 30, 2021.


ę S&P Capital IQ 2021
All news about JW (CAYMAN) THERAPEUTICS CO. LTD
12/03JW Therapeutics Co. Ltd Announces Board and Committee Changes
CI
10/04JW CAYMAN THERAPEUTICS : Therapeutics Awards 7 Million Share Options, Nearly 5 Million Res..
MT
09/28JW (CAYMAN) THERAPEUTICS : to Start Clinical Trials of Multiple Myeloma Treatment in China
MT
09/27JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
CI
09/26JW CAYMAN THERAPEUTICS : Therapeutics Says Immunotherapy Shows Long-Term Efficacy in Large..
MT
09/26JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel ..
CI
09/06JW CAYMAN THERAPEUTICS : Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel..
AQ
09/03JW CAYMAN THERAPEUTICS : China Approves JW Therapeutics' Immunotherapy for Lymphoma Treatm..
MT
09/03JW Therapeutics Co. Ltd Announces NMPA Approval of Relmacabtagene Autoleucel Injection ..
CI
08/27JW Therapeutics Co. Ltd Reports Unaudited Consolidated Earnings Results for the Six Mon..
CI
More news
Financials
Sales 2021 103 M 16,2 M 16,2 M
Net income 2021 -629 M -99,2 M -99,2 M
Net cash 2021 1 897 M 299 M 299 M
P/E ratio 2021 -8,41x
Yield 2021 -
Capitalization 4 701 M 603 M 741 M
EV / Sales 2021 27,3x
EV / Sales 2022 7,31x
Nbr of Employees 477
Free-Float 56,1%
Chart JW (CAYMAN) THERAPEUTICS CO. LTD
Duration : Period :
JW (Cayman) Therapeutics Co. Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JW (CAYMAN) THERAPEUTICS CO. LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 11,56 CNY
Average target price 24,58 CNY
Spread / Average Target 113%
EPS Revisions
Managers and Directors
Yi Ping Li Chairman & Chief Executive Officer
Xin Fu Chief Financial Officer & Senior Vice President
Lapyuen Harry Lam Chief Technology Officer & Executive VP
Chi Shing Li Independent Non-Executive Director
Yiu Leung Cheung Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
JW (CAYMAN) THERAPEUTICS CO. LTD-56.13%571
GILEAD SCIENCES, INC.19.55%87 368
BIONTECH SE243.27%73 106
REGENERON PHARMACEUTICALS31.46%66 402
WUXI APPTEC CO., LTD.24.26%63 075
VERTEX PHARMACEUTICALS-13.17%52 178